Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
52.90
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
64
65
Next >
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
February 22, 2024
Via
Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
February 21, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
February 09, 2024
Via
Benzinga
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
The 3 Best Stocks Beginning Investors Can Buy: February 2024
February 21, 2024
Starting your investment journey? Navigate the market with confidence! Discover 3 stocks for beginning investors in this article.
Via
InvestorPlace
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside
February 21, 2024
Shares of these companies are trading at sizable earnings discounts.
Via
The Motley Fool
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
February 20, 2024
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
February 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
February 17, 2024
Patience will be rewarded with these stocks.
Via
The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
February 14, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
February 12, 2024
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.
Via
InvestorPlace
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
Via
Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
February 08, 2024
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
Via
Investor's Business Daily
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
February 07, 2024
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.
Via
InvestorPlace
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
February 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
64
65
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.